JNJ

Johnson and Johnson (JNJ)

Johnson and Johnson

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:JNJ

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/09/23	19 : 32	IH Market News	Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More	NYSE:JNJ	Johnson and Johnson
2024/09/21	07 : 53	Business Wire	Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt	NYSE:JNJ	Johnson and Johnson
2024/09/21	05 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:JNJ	Johnson and Johnson
2024/09/21	04 : 43	Business Wire	Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims	NYSE:JNJ	Johnson and Johnson
2024/09/20	07 : 54	PR Newswire (US)	RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer	NYSE:JNJ	Johnson and Johnson
2024/09/17	19 : 40	IH Market News	Microsoft Boosts Share Buyback, Raises Dividends by 10%, Intel Secures Chip Deal with Amazon	NYSE:JNJ	Johnson and Johnson
2024/09/16	15 : 50	PR Newswire (US)	Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer	NYSE:JNJ	Johnson and Johnson
2024/09/15	15 : 30	PR Newswire (US)	New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer	NYSE:JNJ	Johnson and Johnson
2024/09/14	22 : 45	PR Newswire (US)	RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer	NYSE:JNJ	Johnson and Johnson
2024/09/14	16 : 10	PR Newswire (US)	RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer	NYSE:JNJ	Johnson and Johnson
2024/09/13	05 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:JNJ	Johnson and Johnson
2024/09/13	05 : 43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:JNJ	Johnson and Johnson
2024/09/12	07 : 22	PR Newswire (US)	TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease	NYSE:JNJ	Johnson and Johnson
2024/09/11	06 : 15	PR Newswire (US)	Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)	NYSE:JNJ	Johnson and Johnson
2024/09/11	05 : 26	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:JNJ	Johnson and Johnson
2024/09/09	02 : 47	PR Newswire (US)	RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer	NYSE:JNJ	Johnson and Johnson
2024/09/06	05 : 30	Business Wire	Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results	NYSE:JNJ	Johnson and Johnson
2024/09/05	19 : 11	IH Market News	Qualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual Listing	NYSE:JNJ	Johnson and Johnson
2024/09/04	05 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:JNJ	Johnson and Johnson
2024/08/31	04 : 51	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:JNJ	Johnson and Johnson
2024/08/30	03 : 05	Edgar (US Regulatory)	Form N-PX - Annual Report of proxy voting record of management investment companies	NYSE:JNJ	Johnson and Johnson
2024/08/29	21 : 00	PR Newswire (US)	Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis	NYSE:JNJ	Johnson and Johnson
2024/08/27	21 : 00	PR Newswire (US)	Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress	NYSE:JNJ	Johnson and Johnson
2024/08/27	05 : 26	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:JNJ	Johnson and Johnson
2024/08/26	21 : 58	IH Market News	IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts	NYSE:JNJ	Johnson and Johnson
2024/08/26	21 : 00	Business Wire	Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024	NYSE:JNJ	Johnson and Johnson
2024/08/21	21 : 12	IH Market News	Walmart Sells JD.com Stake, Microchip Suffers Cyberattack, Union Pacific Warns of Strike in Canada, and Latest News	NYSE:JNJ	Johnson and Johnson
2024/08/20	20 : 30	Business Wire	Johnson & Johnson to Acquire V-Wave	NYSE:JNJ	Johnson and Johnson
2024/08/20	20 : 00	PR Newswire (US)	RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer	NYSE:JNJ	Johnson and Johnson
2024/08/15	19 : 05	IH Market News	Google Mandated to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys Kellanova	NYSE:JNJ	Johnson and Johnson